
|Articles|December 18, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Outlook for BRAF Inhibitors in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Read more about BRAF inhibitors for the treatment of melanoma and
Articles in this issue
almost 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasalmost 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaalmost 12 years ago
Advances in Metastatic Melanomaabout 12 years ago
Targeted Therapies in Basal Cell Carcinomaabout 12 years ago
The Treatment of Melanoma With Emerging Targeted TherapiesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5







































